-+ 0.00%
-+ 0.00%
-+ 0.00%

Baird Maintains Outperform on Denali Therapeutics, Raises Price Target to $34

Benzinga·04/07/2026 10:48:23
Listen to the news
Baird analyst Joel Beatty maintains Denali Therapeutics (NASDAQ:DNLI) with a Outperform and raises the price target from $32 to $34.